Venous Thromboembolism Treatment Market: by Drug Type ( Factor Xa inhibitors, Thrombolytic therapy,Plasminogen activators,Fondaparinux,Dabigatran,Warfarin), Disease Type ( Deep vein thrombosis, Pulmonary embolism), Distribution Channel (Hospital pharmacies, Online Pharmacies, Retail pharmacies) - Geography

   

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The venous thromboembolism treatment market is growing at a significant CAGR of 9% during the forecast period 2022 to 2028 due to increase in geriatric population. The Global Venous Thromboembolism Treatment Market is forecasted to grow at a High CAGR during the forecast period (2018-2024). Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism. Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins. The growth of global venous thromboembolism treatment market is due to rise in prevalence of venous thromboembolism (According to the International Society of Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism treatment market share. For instance, in March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients. Similarly, in May 2011, Eliquis (apixaban) Approved In Europe for preventing venous thromboembolism after elective knee or hip replacement. Also, in January 2015, Bayer forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.

Global Venous Thromboembolism Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

9%

Largest Market

North-America

Fastest Growing Market

Europe
Venous Thromboembolism Treatment Market Dynamics

Increase in the incidence of venous thromboembolism are fuelling the Venous Thromboembolism (VTE) Treatment Market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period. However, a high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism drugs market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Venous Thromboembolism Treatment Market Segmentation

Drug Type
  • Factor Xa inhibitors
  • Thrombolytic therapy
  • Plasminogen activators
  • Fondaparinux
  • Dabigatran
  • Warfarin
Disease Type
  • Deep vein thrombosis
  • Pulmonary embolism
Distribution Channel
  • Hospital pharmacies
  • Online Pharmacies
  • Retail pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1. Executive summary 2. Global Venous Thromboembolism Market Introduction 2.1. Global Venous Thromboembolism Market – Taxonomy 2.2. Global Venous Thromboembolism Market –Definitions 2.2.1. Drug Type 2.2.2. Disease Type 2.2.3. End User 3. Global Venous Thromboembolism Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Venous Thromboembolism Market Dynamics – Factors Impact Analysis 3.6. Global Venous Thromboembolism Market – Regulations 3.6.1. U.S 3.6.2. Europe 3.6.3. Japan 3.6.4. China 3.7. Global Venous Thromboembolism Market – Product Innovations 4. Global Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Venous Thromboembolism (VTE) Treatment Market Oppurtunity Analysis 5. Global Venous Thromboembolism Market, By Drug Type, 2013 - 2017 and Forecast, 2018 - 2024 5.1. Factor Xa inhibitors 5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.3. Market Opportunity Analysis 5.2. Thrombolytic therapy 5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.3. Market Opportunity Analysis 5.3. Plasminogen activators 5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.3.3. Market Opportunity Analysis 5.4. Fondaparinux 5.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.4.3. Market Opportunity Analysis 5.5. Dabigatran 5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.5.3. Market Opportunity Analysis 5.6. Warfarin 5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.6.3. Market Opportunity Analysis 6. Global Venous Thromboembolism Market Forecast, By Disease Type, 2013 - 2017 and Forecast, 2018 - 2024 6.1. Deep Vein Thrombosis 6.1.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis 6.2. Pulmonary Embolism 6.2.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis 7. Global Venous Thromboembolism Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024 7.1. Hospital pharmacies 7.2. Online Pharmacies 7.3. Retail pharmacies 7.3.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.3.3. Market Opportunity Analysis 8. Global Venous Thromboembolism Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 8.1. North America 8.1.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis 8.2. Europe 8.2.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis 8.3. Asia-Pacific 8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.3.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis 8.4. Latin America 8.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.4.3. Market Opportunity Analysis 8.5. Middle East and Africa 8.5.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.5.3. Market Opportunity Analysis 8.6. Global Venous Thromboembolism Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2018 – 2024 9. North America Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 9.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.1.1. Factor Xa inhibitors 9.1.2. Thrombolytic therapy 9.1.3. Plasminogen activators 9.1.4. Fondaparinux 9.1.5. Dabigatran 9.1.6. Warfarin 9.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.2.1. Deep vein thrombosis 9.2.2. Pulmonary embolism 9.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.3.1. Hospital Pharmacies 9.3.2. Online Pharmacies 9.3.3. Retail Pharmacies 9.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 9.4.1. U.S. 9.4.2. Canada 9.5. North America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024 9.6. North America Venous Thromboembolism Market Dynamics – Trends 10. Europe Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 10.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.1. Factor Xa inhibitors 10.1.2. Thrombolytic therapy 10.1.3. Plasminogen activators 10.1.4. Fondaparinux 10.1.5. Dabigatran 10.1.6. Warfarin 10.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.2.1. Deep vein thrombosis 10.2.2. Pulmonary embolism 10.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.3.1. Hospital Pharmacies 10.3.2. Online Pharmacies 10.3.3. Retail Pharmacies 10.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.4.1. Germany 10.4.2. UK 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Russia 10.4.7. Poland 10.4.8. Rest of Europe 10.5. Europe Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024 10.6. Europe Venous Thromboembolism Market Dynamics – Trends 11. Asia-Pacific Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 11.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.1. Factor Xa inhibitors 11.1.2. Thrombolytic therapy 11.1.3. Plasminogen activators 11.1.4. Fondaparinux 11.1.5. Dabigatran 11.1.6. Warfarin 11.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.2.1. Deep vein thrombosis 11.2.2. Pulmonary embolism 11.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.3.1. Hospital Pharmacies 11.3.2. Online Pharmacies 11.3.3. Retail Pharmacies 11.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.4.1. Japan 11.4.2. China 11.4.3. India 11.4.4. ASEAN 11.4.5. Australia & New Zealand 11.4.6. Rest of Asia-Pacific 11.5. Asia-Pacific Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024 11.6. Europe Venous Thromboembolism Market Dynamics – Trends 12. Latin America Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 12.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.1. Factor Xa inhibitors 12.1.2. Thrombolytic therapy 12.1.3. Plasminogen activators 12.1.4. Fondaparinux 12.1.5. Dabigatran 12.1.6. Warfarin 12.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.2.1. Deep vein thrombosis 12.2.2. Pulmonary embolism 12.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.3.1. Hospital Pharmacies 12.3.2. Online Pharmacies 12.3.3. Retail Pharmacies 12.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Argentina 12.4.4. Venezuela 12.4.5. Rest of Latin America 12.5. Latin America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024 12.6. Latin America Venous Thromboembolism Market Dynamics – Trends 13. Middle East and Africa Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 13.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.1. Factor Xa inhibitors 13.1.2. Thrombolytic therapy 13.1.3. Plasminogen activators 13.1.4. Fondaparinux 13.1.5. Dabigatran 13.1.6. Warfarin 13.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.2.1. Deep vein thrombosis 13.2.2. Pulmonary embolism 13.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.3.1. Hospital Pharmacies 13.3.2. Online Pharmacies 13.3.3. Retail Pharmacies 13.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.4.1. Gulf Cooperation Council (GCC) Countries 13.4.2. Israel 13.4.3. South Africa 13.4.4. Rest of MEA 13.5. MEA Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024 13.6. MEA Venous Thromboembolism Market Dynamics – Trends 14. Competition Landscape 14.1. Strategic Dashboard of Top Market Players 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 14.2.1. Sanofi (France) 14.2.2. Pfizer Inc. (U.S.) 14.2.3. Daiichi Sankyo Co. Ltd. (Japan) 14.2.4. Bristol Myers Squibb (U.S.) 14.2.5. Johnson & Johnson Services, Inc. (U.S.) 14.2.6. AbbVie Inc. (U.S.) 14.2.7. Merck & Co. (U.S.) 14.2.8. Astellas Pharma Inc. (Japan) 14.2.9. Sawai Pharmaceuticals Co. Ltd. (U.S.) 14.2.10. Abbott Laboratories (U.S.) 14.2.11. Wockhardt Ltd (India) 14.2.12. Bayer AG (Germany) 14.2.13. Dupont Pharm Co. (U.S.) 15. Research Methodology 16. Key Assumptions and Acronyms
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • Daiichi Sankyo Co. Ltd. (Japan)
  • Bristol Myers Squibb (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Merck & Co. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • Sawai Pharmaceuticals Co. Ltd. (U.S.)
  • Abbott Laboratories (U.S.)
  • Wockhardt Ltd (India)
  • Bayer AG (Germany)
  • Dupont Pharm Co. (U.S.)